semax mastery course
Unit 9 of 11
dosing & administration
clinical protocols, community use, and harm reduction
dosing protocols for educational purposes
This unit documents both the approved clinical dosing protocols used in Russian medicine and the community-reported regimens used by nootropic users outside of clinical supervision. None of this constitutes medical advice. No dosing regimen described here has been validated by Western regulatory agencies, and product quality from unregulated sources varies significantly.
dosing reference tool
explore the interactive visualization for this unit.
dosing reference tool
dosing at a glance
key numbers from approved Russian clinical protocols.
0.1% standard
~50 mcg per drop -- cognitive and optic nerve use at 200-600 mcg/day
1% stroke dose
~500 mcg per drop -- hospital setting at 2,000-6,000 mcg/day
10-14 days
standard treatment course length with 1-4 week rest periods
intranasal
primary route -- 60-70% bioavailability via nasal mucosa and olfactory pathway
The dosing information in this unit documents approved Russian clinical protocols and community-reported regimens for educational purposes only. None of this constitutes medical advice. No dosing regimen described here has been validated by Western regulatory agencies, and product quality from unregulated sources varies significantly.
key terms
definitions for the dosing and administration concepts in this unit.
M
The nasal lining's built-in cleaning mechanism that continuously sweeps deposited material toward the throat. The clearance half-time is approximately 15-20 minutes, creating a window during which the peptide must be absorbed before being cleared. This is why gentle inhalation (not forceful sniffing) and proper head positioning are important -- you want the peptide to stay on the absorptive surface.
B
Sterile water containing 0.9% benzyl alcohol as a preservative, used for reconstituting lyophilized peptide powders. The preservative prevents bacterial growth in multi-use vials. Sterile water without preservative can be used but must be consumed within 24-48 hours. For Semax: 5 mg powder + 5 mL BAC water = 1 mg/mL (0.1% solution), with each 50 mcL drop delivering approximately 50 mcg.
S
Combining multiple peptides or nootropics in a concurrent regimen. The most common Semax stack is with Selank -- Semax provides nootropic/dopaminergic effects while Selank provides anxiolytic/GABAergic effects. Both share the PGP extension and intranasal route. No stacking protocol has been validated in clinical trials.
C
Alternating periods of use ("on") and non-use ("off") to prevent tolerance and maintain receptor sensitivity. The Russian clinical protocol uses 10-14 days on, 1-4 weeks off. Community users experiment with longer cycles (3-4 weeks on, 1-2 weeks off) or weekday-only patterns, but no controlled research validates these alternatives.
O
The upper posterior region of the nasal cavity where olfactory receptor neurons provide a direct pathway from the nose to the brain. Directing Semax drops toward this area maximizes nose-to-brain transport via olfactory nerve fibers, bypassing the blood-brain barrier entirely. Proper head positioning (tilted back ~15-20 degrees) helps target this region.
dosing Semax -- the simple version
how much, how often, and why intranasal is the only practical route.
For cognitive use, the standard Russian formulation is a 0.1% nasal solution -- roughly 50 mcg per drop. Typical daily exposure is 200-600 mcg/day, split across 2-3 administrations during the morning and early afternoon. Evening doses can interfere with sleep because of the dopaminergic and noradrenergic modulation, so most users stop dosing by mid-afternoon.
For acute ischemic stroke, the protocol is entirely different. The 1% solution (~500 mcg per drop) is given in a hospital setting at 2,000-6,000 mcg/day during the first 5-10 days after stroke onset. This is not a community-relevant regimen -- it requires medical supervision, a defined neuroprotective window, and stroke-care infrastructure.
Cycling and breaks matter. Russian protocols specify 10-14-day courses with 1-4-week washouts, and that's the envelope where safety has been characterized. Running Semax continuously for months is outside the studied range; the community pattern of "daily indefinitely" is an uncontrolled experiment.
A
Intranasal Semax achieves systemic bioavailability roughly in the 60-70% range based on Russian pharmacokinetic data, though Western journal replication is limited. Plasma half-life is short (minutes), but biological effects persist substantially longer -- a pattern consistent with the nose-to-brain pathway delivering peptide to CNS tissue at concentrations above what plasma exposure alone would predict. For the 0.1% solution: 5 mg powder + 5 mL bacteriostatic water gives 1 mg/mL, so each ~50 mcL drop delivers approximately 50 mcg. Mucociliary clearance (the nasal lining's continuous sweep toward the throat) has a 15-20-minute half-time, which is the window during which absorption must occur.
advanced: why intranasal beats subq for this peptide
Most peptides do not cross the blood-brain barrier (BBB) from systemic circulation -- the tightly junctioned endothelium blocks them. Subcutaneous injection produces high and predictable plasma levels (~60-80% bioavailability) but still has to cross the BBB to reach the brain, which Semax does poorly. Intranasal delivery solves this by exploiting the olfactory nerve pathway: nerve endings in the upper nasal cavity (olfactory cleft) connect directly to the olfactory bulb, and from there to the hippocampus, amygdala, and cortex. Radiolabeled rodent studies show intranasally administered Semax reaches these brain regions at concentrations higher than would be expected from blood circulation alone. For a peptide whose targets are central, the BBB bypass via the olfactory route is the practical reason subq has never been the standard route.
advanced: compounding pharmacy considerations
Outside Russia and Ukraine, Semax has no licensed manufacturer and no approved compounding monograph. US users typically buy lyophilized "research chemical" powder from peptide vendors and reconstitute in bacteriostatic water (0.9% benzyl alcohol). Product quality varies significantly between vendors -- third-party HPLC verification is the only practical way to confirm identity and purity. Compounding pharmacies may produce nasal sprays on a per-prescription basis where local rules allow, but no compounded product has been validated against the Russian regulatory standard. Cold-chain handling (refrigerated 2-8 C after reconstitution, used within a few weeks) materially affects potency.
intranasal vs subcutaneous vs intravenous
how the three plausible delivery routes for Semax compare -- and why one of them is the default.
intranasal
- typical dose: 200-600 mcg/day (cognitive) or 2,000-6,000 mcg/day (acute stroke)
- onset: minutes via nasal mucosa + olfactory pathway
- duration: biological effects persist hours despite short plasma half-life
- drawbacks: mild nasal irritation; technique matters (drops, not sniff)
subcutaneous
- typical dose: not used in any approved protocol; community-only and rare
- onset: 15-30 minutes systemic, but CNS effects depend on BBB crossing
- duration: higher and more predictable plasma levels (60-80% bioavailability)
- drawbacks: Semax crosses the BBB poorly -- high plasma may not translate to high CNS exposure; injection-site and contamination risks
intravenous
- typical dose: not part of any approved or community protocol
- onset: immediate plasma peak
- duration: very short -- rapid systemic clearance, still BBB-limited for CNS
- drawbacks: highest infection/embolism risk; offers no CNS advantage over intranasal for this peptide
where this has been studied
dosing data sources -- official protocols, off-label patterns, and pediatric use in Russia.
Russian official protocols
"Heptapeptide Semax" 0.1% nasal drops is the standard cognitive / dyscirculatory-encephalopathy formulation, with indication-specific dose ranges and 10-14-day cycles. The 1% nasal solution is reserved for acute ischemic stroke under hospital supervision. These protocols are the source of the dose ranges most commonly quoted in community discussion.
NASA off-label patterns
N-Acetyl Semax Amidate (NASA) is a community modification with an acetylated N-terminus and amidated C-terminus, intended to increase stability and potency. It has been studied in zero formal clinical trials -- dose recommendations circulating in forums are extrapolations from standard Semax, not data.
community microdose protocols
Microdosing patterns sourced from Reddit r/peptides and forum-collated protocols typically use 100-300 mcg/day with continuous daily dosing or weekday-only patterns. None of these regimens have been characterized in peer-reviewed literature -- they exist as community lore, not as research-grade data.
pediatric dosing in Russia
Semax is used in Russian pediatric practice at substantially lower doses for narrow indications including attention disorders and developmental delay. Published protocols specify weight-adjusted ranges and shorter courses than adult use. Western pediatric data is absent.
community-dose escalation diverges from clinical-trial dosing. The Russian clinical envelope is 10-14-day courses at 200-600 mcg/day for cognitive use. Community patterns of running continuous daily dosing for months at progressively higher amounts -- or layering NASA on top of standard Semax -- are not what was studied. Dose escalation does not get you "more benefit" from the published evidence; it gets you outside the safety envelope.